Hisun To Sell Celsion’s ThermoDox In China; Net Profit May Drop 35-45%
This article was originally published in PharmAsia News
Executive Summary
Zhejiang Hisun Pharmaceutical Co., Ltd. signed a letter of intent with U.S.-based Celsion Corporation to exclusively market Celsion’s patented anti-tumor drug ThermoDox (available for infusion or radiofrequency ablation) with the Celsion trademark in China.